DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma
Neuroendocrine Neoplasms
Extra-pulmonary Neuroendocrine Carcinoma

Interventions

DRUG: BI 764532, dose 1
DRUG: BI 764532, dose 2

Sponsor

Boehringer Ingelheim